Aurobindo Pharma USA, a wholly owned subsidiary of the Aurobindo Pharma, entered into a definitive agreement with Lannett Seller Holdco under which Aurobindo Pharma USA will acquire 100% of membership interest in Lannett Company from Lannett Seller Holdco for US$ 250 million.

Lannett Company has a 425k sq ft large cGMP manufacturing facility, located in Seymour, Indiana, USA, capable of manufacturing multiple dosage forms including tablets, capsules, powders and liquids.

The plant has an annual capacity of ~3.6bn tablets and a strong regulatory and DEA compliance track record. The company has built strong expertise in the controlled substances (non-opioids, mainly ADHD) and generic liquids.

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities. Through this acquisition, Aurobindo will gain access to a complementary portfolio of profitable products, a growing Contract Development and Manufacturing Organization (CDMO) business, and a U.S.-based manufacturing facility with significant excess capacity and with potential for further expansion.

The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics for which Aurobindo currently has a limited presence.

This acquisition strengthens Aurobindo’s ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category.

The proposed transaction shall be subject to US Federal Trade Commission approval and any other statutory and government approvals as may be necessary.